-
Views
-
Cite
Cite
Robert D. Murray, Kiwon Kim, Song-Guang Ren, Ian Lewis, Gisbert Weckbecker, Christian Bruns, Shlomo Melmed, The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion, The Journal of Clinical Endocrinology & Metabolism, Volume 89, Issue 6, 1 June 2004, Pages 3027–3032, https://doi.org/10.1210/jc.2003-031319
Close - Share Icon Share
Abstract
Currently available somatostatin analogs predominantly bind to the somatostatin receptor subtype (SSTR)2 subtype, and control GH and IGF-I secretion in approximately 65% of patients with acromegaly, their efficacy relating to receptor density and subtype expression. SOM230 is a somatostatin ligand with high affinity to four SSTR subtypes. In primary cultures of rat pituicytes, SOM230 dose-dependently inhibited GH release (P = 0.002) with an IC50 of 1.2 nm. Ten nanomoles SOM230 inhibited GH and TSH release by 40 ± 7% (P < 0.001) and 47 ± 21% (P = 0.09), respectively. No effect of SOM230 was observed on prolactin (PRL) or LH release. In cultures of human fetal pituitary cells, SOM230 inhibited GH secretion by 42 ± 9% (P = 0.002) but had no effect on TSH release. SOM230 inhibited GH release from GH-secreting adenoma cultures by 34 ± 8% (P = 0.002), PRL by 35 ± 4% from PRL-secreting adenomas (P = 0.01), and α-subunit secretion from nonfunctioning pituitary adenomas by 46 ± 18% (P = 0.34). In contrast, octreotide inhibited GH, PRL, and α-subunit from the respective adenoma by 18 ± 12 (P = 0.39), 22 ± 4 (P = 0.04), and 20 ± 10% (P = 0.34). In all culture systems, no significant difference in the inhibitory action of SOM230, octreotide, and somatostatin 14 on hormone release was observed. SOM230, similar to somatostatin, has high-affinity binding to SSTR1, 2, 3, and 5 and, in keeping with this, has an equivalent inhibitory effect on pituitary hormone secretion. As a consequence of its broader binding profile, SOM230 is likely to find clinical utility in treating tumors resistant to SSTR-2-preferential analogs.
